Clinical Watch: June 2019

July 18, 2019

In this issue of Clinical Watch, we discuss the FDA guidance on biosimilar interchangeability. We suggest criteria for a new gene therapy that is currently the most expensive drug in the world and review real-world costs associated with psychotropic polypharmacy in patients with cancer. Finally, we review claims data to identify asthma patients being treated with a short-acting beta agonist only.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Flipbook
Telemedicine offers new strategies to improve Medicaid programs
Telemedicine offers new strategies to improve Medicaid programs

Telemedicine offers new strategies to improve Medicaid programs

Next Flipbook
Clinical Watch: May 2019
Clinical Watch: May 2019

In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a...